Cue biopharma, inc. (CUE)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Cash flows from operating activities
Net loss

-12,818

-8,916

-6,991

-9,524

-11,267

-11,621

-12,551

-7,285

-7,523

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-3,350

Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization

263

-

-

-

205

-

-

-

-

-

-

-

-

Deferred rent

-

-

-

-

-

-157

-149

-66

27

-

-

-

-

Depreciation

-

-

-

-

-

-

194

195

167

126

124

102

67

Deferred rent

-

-

-

-

-

-

-

-

-

27

27

28

27

Stock-based compensation

3,175

1,995

1,440

1,317

1,768

2,010

2,730

1,275

1,158

774

751

707

543

Operating lease right of use amortization

998

1,318

1,023

1,012

1,001

-

-

-

-

-

-

-

-

Non-cash investment expense (income)

-30

-

-

-

45

-

-

-

-

-

-

-

-

Other non cash charges

-

-

-

-6

5

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Account receivable

-150

-

-

-

-

-

-

-

-

-

-

-

-

Research and development contract advances

-

-

-

-

-

-

-

-

-531

-

-

-

-423

Prepaid expenses and other current assets

994

-141

-793

222

225

600

-2,084

1,704

481

816

-192

472

20

Operating lease liability

-1,087

-1,248

-1,505

-768

-756

-

-

-

-

-

-

-

-

Deposits

-

-

-

-

-

-

-

509

-1,060

50

-8

0

-101

Accounts payable

717

-295

-1,111

-604

858

1,038

453

-724

-391

-

-

-

-

Accrued expenses

-1,083

672

-1,025

431

361

-480

1,144

572

-599

-

-

-

-

Research and development contract liability

-295

-293

-375

1,967

-370

5,498

-449

109

-472

-

-

-

-

Net cash used in operating activities

-10,944

-6,437

-9,208

-6,676

-8,475

-3,897

-6,298

-6,456

-9,759

-

-

-

-

Cash flows from investing activities
Accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-76

Accrued compensation and related expenses

-

-

-

-

-

-

-

-

-

-

-

-

-77

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-3,464

Purchases of property and equipment

-

10

17

0

19

120

301

760

673

18

208

247

556

Redemption of short term investments

-

-

-

-5,000

-9,500

-

-

-

-

-

-

-

-

Purchases of marketable securities

9,950

-

-

-

-

-

-

-

-

-

-

-

-

Net cash (used in) provided by investing activities

-9,950

-15,145

3,984

5,127

9,481

4,686

-23,608

-760

-673

-

-

-

-

Cash flows from financing activities
Proceeds from exercise of stock options

36

-

-

-

257

-

-

-

-

-

-

-

-

Net cash provided by financing activities

36

34,493

12,292

3,747

257

-

-

-

-

-

-

-

-

Net increase/(decrease) in cash, cash equivalents, and restricted cash

-20,858

12,910

7,068

2,198

1,263

4,958

-29,894

-7,216

-10,432

-

-

-

-

Supplemental disclosures of non-cash investing activities:
Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-556

Net increase (decrease) in cash

-

-

-

-

-

-

-

-

-

-

-

-

-4,020

Purchases of property and equipment in accounts payable or accrued expenses

140,645

-

-

-

-

-

-

-

227

-

-

-

29

Accrual of deferred offering costs

-

-

-

-

-

-

-

-

-

-

38

83

76